

Gemcitabine (1000mg/m²) and Capecitabine (830mg/m²) Therapy - 28 day

INDICATIONS FOR USE:

| INDICATION | ICD10 | Regimen Code | Reimbursement status |
|--|-------|--------------|--|
| Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection | C25 | 00524a | Gemcitabine – Hospital Capecitabine – CDS |

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Gemcitabine is administered on day 1, 8 and 15 and capecitabine is taken on day 1-21 of a 28 day cycle for up to 6 cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

| Day | Drug | Dose | Route | Diluent & Rate | Cycle |
|--------|--------------|---|-------------|-----------------------------|---------------|
| 1,8,15 | Gemcitabine | 1000mg/m ² | IV infusion | 250ml NaCl 0.9% over 30mins | Every 28 days |
| 1 -21 | Capecitabine | 830mg/m ² Twice Daily ^{a, b, c} | PO | N/A | Every 28 days |

^aThe dose to be administered should consider the available tablet strengths.
Reference the NCCP DOSE BANDING TABLES [here](#) for guidance on dosing of capecitabine.
Tablets should be swallowed whole with plenty of water with food or within 30 minutes of eating. Tablets should not be crushed or cut.

^b(Total daily dose = 1660mg/m²)

^c See dose modifications section for patients with identified partial DPD deficiency.

ELIGIBILITY:

- Indications as above
- ECOG 0-2

EXCLUSIONS:

- Hypersensitivity to gemcitabine, capecitabine or any of the excipients
- Known complete DPD deficiency
- History of severe and unexpected reactions to fluoropyrimidine therapy
- Pregnancy and lactation
- Severe hepatic or renal impairment

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

| | | |
|--|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 1 of 7 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

TESTS:

Baseline tests:

- FBC, renal and liver profile
- DPD testing prior to first treatment with capecitabine using phenotype and/or genotype testing unless patient has been previously tested

Regular tests:

- Day 1: FBC, renal and liver profile
- Day 8 and Day 15: FBC

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Consider a reduced starting dose in patients with identified partial DPD deficiency.
 - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
- Any dose modification should be discussed with a Consultant.

Haematological:

Prior to commencing a new treatment cycle (i.e. day 1), ANC must be $\geq 1 \times 10^9/L$ and platelets $\geq 100 \times 10^9/L$.

Table 1: Dose modifications for gemcitabine and capecitabine within a cycle

| ANC ($\times 10^9 /L$) | | Platelet count ($\times 10^9 /L$) | | Other toxicity | Recommended dose of Gemcitabine | Recommended dose of Capecitabine |
|--|-----|-------------------------------------|----|--|---|--|
| ≥ 1 | and | ≥ 100 | | | 100 % | 100% |
| 0.5- 1 | or | 50-100 | | | 75% | 100% |
| < 0.5 | or | <50 | | | Omit. Do not restart treatment until ANC ≥ 0.5 and platelets ≥ 50 | Interrupt treatment until recovery of toxicity to \leq Grade 1 |
| ANC < 0.5 for ≥ 5 days or ANC < 0.1 for ≥ 3 days or Any incidence of febrile neutropenia | or | < 25 | or | cycle delay of >1 week due to any toxicity | Reduce dose to 75% of the original cycle initiation dose for all subsequent cycles. | Interrupt treatment until recovery of toxicity to \leq Grade 1 |

| | | |
|---|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 2 of 7 |

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Renal and hepatic impairment:

Table 2: Dose modifications for capecitabine and gemcitabine in renal and hepatic impairment

| Drug | Renal Impairment | | Hepatic Impairment |
|---------------|------------------------------------|--|--|
| | Creatinine Clearance (CrCl ml/min) | Dose | |
| Capecitabine* | ≥30 | 100% | In the absence of safety and efficacy data in patients with hepatic impairment, capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis. |
| | <30 | Omit | |
| Gemcitabine | ≥30 | 100% | If bilirubin ≥27 micromol/L, use dose of 800 mg/m ² and increase dose to full dose if tolerated. |
| | <30 | Consider dose reduction – clinical decision. | |

*Reference Table 7 for dose modification of capecitabine in treatment related hepatotoxicity

Management of adverse events:

Table 3: Dose Modification of gemcitabine for Adverse Events

| Adverse reactions | Recommended dose modification of gemcitabine |
|--|--|
| Grade ≥ 2 Pneumonitis | Discontinue gemcitabine |
| Grade > 3 Non-haematological toxicity (except nausea/vomiting) | Therapy with gemcitabine should be withheld (until toxicity has resolved to grade ≤ 1) and may be resumed with 50% dose reduction or treatment discontinued at discretion of prescribing consultant. |
| Grade > 4 Non-haematological toxicity | Discontinue treatment |

Table 4: Dose Modification of Capecitabine for Adverse Events

| Toxicity grades* | Dose changes within a treatment cycle | Dose adjustment for next cycle/dose (% of starting dose) |
|------------------------------|--|--|
| Grade 1 | Maintain dose level | Maintain dose level |
| Grade 2 | Interrupt until resolved to grade 0-1 | 100% |
| • 1 st appearance | | 75% |
| • 2 nd appearance | | 50% |
| • 3 rd appearance | | |
| • 4 th appearance | Discontinue permanently | |
| Grade 3 | Interrupt until resolved to grade 0-1 | 75% |
| • 1 st appearance | | 50% |
| • 2 nd appearance | | |
| • 3 rd appearance | Discontinue permanently | |
| Grade 4 | Discontinue permanently OR If consultant deems it to be in patient's best interest to continue, interrupt until resolved to grade 0-1 | 50% |
| • 1 st appearance | | |
| • 2 nd appearance | Discontinue permanently | |

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.
*Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

| | | |
|--|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 3 of 7 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</p> | | |

Table 5: Dose Modification of capecitabine for diarrhoea

| Grade | Diarrhoea | Dose changes within a treatment cycle | Dose adjustment for next cycle/dose (% of starting dose) |
|-------|---|--|--|
| 0-1 | Increase of 2 to 3 stools/day or nocturnal stools | Maintain dose level | Maintain dose level |
| 2 | Increase of 4 to 6 stools/day or nocturnal stools | Interrupt until resolved to grade 0-1 | 100% |
| | • 1 st appearance | | |
| | • 2 nd appearance | | |
| | • 3 rd appearance | 50% | |
| | • 4 th appearance | Discontinue permanently | |
| 3 | Increase of 7 to 9 stools/day or incontinence | Interrupt until resolved to grade 0-1 | 75% |
| | • 1 st appearance | | 50% |
| | • 2 nd appearance | Discontinue permanently | |
| | • 3 rd appearance | | |
| 4 | Increase of 10 or more stools/day or grossly bloody diarrhoea; may require parenteral support | | |
| | • 1 st appearance | Discontinue permanently or If consultant deems it to be in patient's best interest to continue, interrupt until resolved to grade 0-1 | 50% |
| | • 2 nd appearance | Discontinue permanently | |

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy

Hand foot syndrome:

Table 6: Dose modification of capecitabine in hand foot syndrome

| Toxicity Grade | | Dose Modification |
|----------------|---|--|
| Grade 1 | Skin changes (e.g., numbness, dysesthesia, paraesthesia, tingling, erythema) with discomfort not disrupting normal activities | 100% Dose |
| Grade 2 | Skin changes (e.g., erythema, swelling) with pain affecting activities of daily living | Withhold treatment until event resolves or decreases in intensity to grade 1. |
| Grade 3 | Severe skin changes (e.g., moist desquamation, ulceration, blistering) with pain, causing severe discomfort and inability to work or perform activities of daily living | Withhold treatment until event resolves or decreases in intensity to grade 1. Subsequent doses of capecitabine should be decreased |

| | | |
|--|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 4 of 7 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |

Treatment related hepatotoxicity

Table 7: Dose modification of capecitabine in treatment related hepatotoxicity

| Bilirubin | | ALT, AST | Dose Modification |
|-------------|----|-------------|---|
| > 3.0 x ULN | or | > 2.5 x ULN | Withhold treatment until bilirubin decreases to ≤ 3.0 x ULN or ALT, AST decrease to ≤ 2.5 x ULN |

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Gemcitabine: Low (**Refer to local policy**)

Capecitabine: Minimal to low (**Refer to local policy**)

PREMEDICATIONS: Not usually required

OTHER SUPPORTIVE CARE: Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) (**Refer to local policy**).

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.

Gemcitabine:

- **Pulmonary Toxicity:** Acute shortness of breath may occur. Discontinue treatment with gemcitabine if drug-induced pneumonitis is suspected.
- **Cardiovascular:** Due to the risk of cardiac and/or vascular disorders with gemcitabine, particular caution must be exercised with patients presenting a history of cardiovascular events.
- **Haemolytic Uraemic syndrome:** Irreversible renal failure associated with hemolytic uremic syndrome may occur (rare) with gemcitabine. Use caution with pre-existing renal dysfunction.

Capecitabine:

- **Diarrhoea and dehydration:** This may be dose limiting with capecitabine therapy. Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.
- **Cardiotoxicity:** Angina-like chest pain, tachycardia, arrhythmias, heart failure, myocardial infarction and cardiac arrest may occur with capecitabine especially in patients with a prior history of coronary artery disease.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency:** DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil,

| | | |
|---|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 5 of 7 |

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.

- **Hand-foot syndrome (HFS):** HFS, also known as palmar-plantar erythrodysesthesia (PPE), is a common side effect associated with capecitabine (see Table 6 for dose modification of capecitabine for HFS).

DRUG INTERACTIONS:

- Capecitabine enhances the anticoagulant effect of warfarin. Patients taking coumarin derivative anticoagulants should be monitored regularly for alterations in their coagulation parameters and the anti-coagulant dose adjusted accordingly.
- Sorivudine inhibits dihydropyrimidine dehydrogenase thus increasing its toxicity. Therefore capecitabine must not be administered concomitantly with sorivudine or its chemically related analogues.
- Patients taking phenytoin or fosphenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

1. Neoptolemos J, Palmer D et al. Comparison of adjuvant Gemcitabine and Capecitabine with Gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
2. Knox J, Hedley D, Oza A. et al. Combining Gemcitabine and Capecitabine in Patients with Advanced Biliary Cancer: A phase 11 Trial. *Journal of Clinical Oncology* 2005;23(10), 2332-2338
3. BCCA Protocol Summary for Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine- GIPAJGCAP (reviewed Nov 2017)
4. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network.
5. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009;North London Cancer Network.
6. HPRA Direct Healthcare Professional Communication. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Accessed Aug 2020 Available at: [https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-\(i-v\)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0](https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-(i-v)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0)
7. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V4 2022. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
8. Gemcitabine 40 mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics. Accessed Sept 2020. Available at: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2059-039-001_18042019163629.pdf
9. Capecitabine (Xeloda®) Summary of Product Characteristics. Accessed Sept 2020. Available at:

| | | |
|---|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 6 of 7 |

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR - Product_Information/human/000316/WC500058151.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000316/WC500058151.pdf)

| Version | Date | Amendment | Approved By |
|---------|------------|--|-------------------|
| 1 | 17/10/2018 | | Prof Maccon Keane |
| 2 | 11/03/2020 | Updated capecitabine dosing in renal impairment | Prof Maccon Keane |
| 3 | 02/09/2020 | Reviewed. Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia. | Prof Maccon Keane |
| 4 | 18/01/2023 | Updated dose modification for gemcitabine in hepatic impairment. Amended emetogenic potential. | Prof Maccon Keane |

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

| | | |
|--|---|-------------------|
| NCCP Regimen: Gemcitabine(1000mg/m ²) and Capecitabine (830mg/m ²) Therapy-28 day | Published: 15/11/2018 Review: 23/09/2025 | Version number: 4 |
| Tumour Group: Gastrointestinal NCCP Regimen Code: 00524 | ISMO Contributor: Prof Maccon Keane | Page 7 of 7 |
| <p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p> | | |